<DOC>
	<DOCNO>NCT02102464</DOCNO>
	<brief_summary>The pilot study objective evaluate potential benefit LipiFlow® System treatment contact lens wearer meibomian gland dysfunction evaporative dry eye assess improvement meibomian gland function reduction dry eye symptom comparison untreated control .</brief_summary>
	<brief_title>Treatment Meibomian Gland Dysfunction Dry Eye Contact Lens Wearers</brief_title>
	<detailed_description>This prospective , non-significant risk , open-label , randomized clinical trial LipiFlow® treatment contact lens wearer meibomian gland dysfunction evaporative dry eye . All subject undergo examination determine study eligibility capture Baseline status . Subjects randomize receive LipiFlow® treatment ( Treatment Group ) LipiFlow® treatment ( Untreated Control Group ) . Study endpoint evaluate 3 Months compare Treatment Group Untreated Group . To facilitate subject recruitment , Untreated Control group receive Crossover LipiFlow® treatment ( Crossover Treatment Group ) 3 Months . Both Treatment Crossover Treatment group also evaluate one month receive LipiFlow® treatment .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Diagnosis meibomian gland dysfunction dry eye At least 18 year age Willing comply randomization , attend study visit follow patient instruction Habitual soft contact lens wearer 2 18 hours/day 4 7 days/week No change contact lens type dimension past 3 month Clinician assessment acceptable contact lens fit disinfect solution Tear film interferometry 100 unit less Systemic disease condition cause dry eye Use systemic medication know cause dryness History follow ocular condition past 3 month : surgery , trauma , Herpes infection , recurrent inflammation , punctal plug insertion punctal occlusion Presence follow active condition : ocular infection , ocular inflammation , moderate severe allergic conjunctivitis , severe eyelid inflammation , eyelid abnormality affect lid function , ocular surface abnormality compromise corneal integrity Use treatment meibomian gland dysfunction dry eye except counter lubricant dietary supplement Participation another ophthalmic drug device trial past month Employee , relative employee associate clinical site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>